Product Code: LMFR0026
T-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cutting edge of adoptive T-cell therapy. Both receptors deploy T-cells to target the tumor, but CAR T-cells (CAR-T) are limited to binding to cell surface antigens, while TCR T-cells (TCR-T) recognize peptides (derived from intracellular proteins) presented on the cell surface by the major histocompatibility complex (MHC) class I.
TCR-Ts have so far operated in the shadow of CAR-Ts, but may have the advantage in solid tumors. The first approved CD19-specific CAR-Ts are indicated for hematologic malignancies, but CAR-Ts were less successful against solid tumors.
This report “TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals”published in May 2018 brings you up-to-date regarding key TCR-T players, key TCR-T technologies and product candidates, business models, deals and funding opportunities. The report analyzes the TCR-T pipelines and stakeholders in the field, especially focused and diversified TCR-T companies and their relationship with academia and major pharma/biotech. The report highlights the value of TCR-T assets in terms of partnering economic conditions, acquisition prices and financing rounds.
This report has been prepared by use of in-house databases and desktop search to identify and describe company, product, technology and business/financing profiles which then were evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities. Sources of information are provided by scientific and non-scientific references, e.g. press releases, stock exchange disclosures, presentations, annual reports, fact sheets and patent applications (with hyperlinks leading to the source of information).
Key questions answered:
- Which targets are chosen for developmen of TCR-Ts?
- How close are neoantigen-specific TCR-Ts to the clinic?
- Which technologies are used for generation of T-Cell Receptors?
- Has clinical proof-of-concept been shown for any TCR-T?
- How does the TCR-T pipeline look like?
- What manufacturing strategies and solutions have companies chosen?
- Are next generation TCR-Ts already in development?
- What are the key technologies for a successful TCR-T?
- Who are the key players in the TCR-T field?
- How tough is competition among TCR-T developers?
- Should companies be focused on TCR-Ts only or be diversified into various adoptive T-cell therapeutics?
- Which technologies and assets attract licensees?
- How is the financing situation for TCR-T?
- What are the key success factors for TCR-Ts?
Target audience:
- Leading Pharmaceutical companies
- Suppliers
- Contractors
- Technologists
- R&D staff
- Consultants
- Analyst
- CSO's
- CEO's
- CIO's
- COO's
- Business development managers
- Investors
- Governments
- Agencies
- Industry organisations
- Banks
SAMPLE
Table of Contents
1. Executive Summary
2. Introduction, Overview & Background
3. Technologies
- 3.1. Overview & Discussion
- 3.1.1. Technologies for Discovery of Antigens for TCRs
- 3.1.2. Technologies for Discovery of TCRs
- 3.1.3. Allogeneic T-Cell Technologies
- 3.1.4. Technologies for Next Generation TCR T-Cells
- 3.2. Technologies for Discovery of Targets for TCRs
- 3.2.1. XPRESIDENT
- 3.2.2. Target Selection for SPEAR T-Cells
- 3.2.3. Phosphopeptide Library
- 3.2.4. HTS Platform for Neoantigen Identification
- 3.2.5. pMHC Target Discovery
- 3.2.6. EpiTarget Platform
- 3.2.7. Neoantigen Prediction
- 3.3. Technologies for TCR Discovery
- 3.3.1. SPEAR T-Cell Technology
- 3.3.2. High-Throughput Identification of TUMAP-Restriced TCRs & ActEngine
- 3.3.3. Single Cell Sequencing Platform
- 3.3.4. TCR-GENErator
- 3.3.5. HTS TCR Discovery and Sleeping-Beauty Expression System
- 3.3.6. Natural, High Affinity TCRs (Bellicum)
- 3.3.7. High-throughput cloning and characterisation of naturally selected TCRs
- 3.3.8. Natural TCR Library
- 3.3.9. Natural TCRs from Vaccinated Patients
- 3.3.10. T-Rx Mammalian TCR Display
- 3.3.11. VelociT for T-Cell Receptor Discovery
- 3.3.12. Combinatorial TCR Exchange (CTE)
- 3.3.13. Immune Repertoire Capture
- 3.3.14. E-ALPHA Phage Display
- 3.3.15. TCRL Antibodies
- 3.3.16. ACTolog
- 3.3.17. NEO-STIM
- 3.4. TCR Engineered Allogeneic T-Cells
- 3.4.1. ACTallo
- 3.4.2. universal Immune Cell Therapies (uICT)
- 3.4.3. GammaDelta T-Cells
- 3.4.4. Universal Donor Stem Cells
- 3.4.5. ATO Allogeneic T-Cells
- 3.5. Next Generation Technologies to Improve Safety & Efficacy
- 3.5.1. ARTEMIS Technology
- 3.5.2. CID Technology Platform
- 3.5.3. Custom Cell Engineering Technologies synNotch and Throttle
- 3.5.4. DEACT Technology
- 3.5.5. Dominant TCR Technology
- 3.5.6. RetroNectin and siTCR Vector Technologies
- 3.5.7. Stem-to-T-Cell Technology
- 3.5.8. Transmembrane Immunomodulatory Protein (TIP) Technology
4. Pipeline
- 4.1. Overview & Discussion
- 4.1.1. Proof-of-concept
- 4.1.2. Target Selection
- 4.1.3. T-Cell Sources & Subtypes
- 4.1.4. Use of Switches & Next Generation Constructs
- 4.2. Profiles of MAGE-A Specific TCR T-Cells
- 4.2.1. KITE-718
- 4.2.2. MAGE-A4c1032 T
- 4.2.3. MAGE-A10c796 T
- 4.2.4. TBI-1201
- 4.3. Profiles of NY-ESO-1 Specific TCR T-Cells
- 4.3.1. GSK3377794
- 4.3.2. NYCE T Cells
- 4.3.3. TBI-1301
- 4.4. Profiles of AFP Specific TCR T-Cells
- 4.4.1. AFPc332 T
- 4.4.2. ET1402L1 CAR T-Cells
- 4.5. Profiles of PRAME Specific TCR T-Cells
- 4.5.1. BPX-701
- 4.5.2. MDG1011
- 4.5.3. Dual Switch PRAME TCR T-Cells
- 4.6. Profiles of WT1 Specitic TCR T-Cells
- 4.6.1. CMD-602
- 4.6.2. JTCR016
- 4.6.3. WT1-Specific Transgenic T-Cells
- 4.7. Profiles of Other Target Specific TCR T-Cells
- 4.7.1. IMA201
- 4.7.2. KITE-439
- 4.7.3. LTC-H1
- 4.7.4. TC-210
- 4.7.5. ZI-H04
- 4.7.6. ZI-T01
- 4.8. Profiles of Neoantigen Specific TCR T-Cells
- 4.8.1. IMA101
- 4.8.2. NEO-PTC-01
5. Manufacturing
6. Companies
- 6.1. Company Overview & Discussion
- 6.1.1. Pure Play TCR T-Cell Companies
- 6.1.2. Diversified Companies with TCR-T Activities
- 6.2. Pure Play TCR T-Cell Companies
- 6.2.1. Adaptimmune Therapeutics
- 6.2.2. Gadeta
- 6.2.3. Immatics US
- 6.2.4. Lion TCR
- 6.2.5. Tactiva Therapeutics
- 6.2.6. Zelluna Immunotherapies
- 6.2.7. TCR2 Therapeutics
- 6.3. Profiles of Diversified Companies with TCR-T Activities
- 6.3.1. Adicet Bio
- 6.3.2. AgenTus Therapeutics
- 6.3.3. Bellicum Pharmaceuticals
- 6.3.4. BioNTech
- 6.3.5. Bluebird bio
- 6.3.6. Cell Medica
- 6.3.7. Eureka Therapeutics
- 6.3.8. GlaxoSmithKline
- 6.3.9. Intellia Therapeutics
- 6.3.10. Juno, a Celgene Company
- 6.3.11. Kite, a Gilead Company
- 6.3.12. Medigene
- 6.3.13. Neon Therapeutics
- 6.3.14. Regeneron Pharmaceuticals
- 6.3.15. Takara Bio
- 6.3.16. TC BioPharm
- 6.3.17. Tmunity Therapeutics
- 6.3.18. ZIOPHARM Oncology
- 6.4. Other Companies with TCR-T Activities
- 6.4.1. Alpine Immune Sciences
- 6.4.2. Atreca
- 6.4.3. ImmunoCellular Therapeutics
7. Business Development & Financing
- 7.1. Role of academia for the TCR-T industry
- 7.2. Role of Big Pharma & Biotech for TCR-T
- 7.3. Technology In-Licensing Deals
- 7.4. Collaborative Arrangements
- 7.5. Acquisitions of Companies and Assets
- 7.6. Financing of TCR-T Companies
8. Outlook & Perspectives
9. References
List of Tables
- Table 1: Overview of Corporate Technologies to Discover pMHC Targets for TCRs
- Table 2: Overview of Corporate Technologies to Discover Therapeutic TCRs
- Table 3: Overview of Corporate Technologies of TCR-Engineered Allogeneic T-Cells
- Table 4: Overview of Corporate Technologies to Improve Safety & Efficacy of TCR T-Cells
- Table 5: Overview of TCR T-Cell Constructs in Development
- Table 6: Overview of Company Solutions for Manufacturing of Vector & Cells
- Table 7: Overview of in-house Company Manufacturing Solutions
- Table 8: Overview of Company Choices of CMO
- Table 9: Overview of Company Manufacturing Collaborations with Academia/Hospitals
- Table 10: Overview of TCR T-Cell Company Profiles
- Table 11: Overview of Profiles of Pure Play TCR-T Companies
- Table 12: Overview of Profiles of Diversified Companies with TCR-T Activities
- Table 13: Adaptimmune's Pipeline of SPEAR T-Cells
- Table 14: TCR T-cell Pipeline of Lion TCR
- Table 15: TCR2 Therapeutics' TRuC-T Cell Pipeline
- Table 16: TCR T-Cell Pipeline of Zelluna Immunotherapy
- Table 17: Bellicum Pharmaceuticals' Pipeline
- Table 18: Cell Medica's Pipeline
- Table 19: Overview of Kite Pharma's Access to Technologies with Focus on TCR
- Table 20: NCI Programs of TCR T-Cells under CRADA with Kite
- Table 21: TC BioPharm's Pipeline of γδ T-cell programs
- Table 22: Clinical Pipeline of Tmunity Therapeutics
- Table 23: Technology Spin-Out from Academia
- Table 24: Deals with Major Pharma & Biotech
- Table 25: Technology In-Licensing from Pharma & Biotech
- Table 26: Collaborations & Joint Ventures
- Table 27: Acquisitions
- Table 28: Financing Sources of Pure Play TCR-T Companies
- Table 29: Financing Sources of Selected Diversified Companies with TCR-T Activities